| MeSH term | MeSH ID | Detail |
|---|---|---|
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hernia, Hiatal | D006551 | 3 associated lipids |
| HIV Seropositivity | D006679 | 15 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Hyperemesis Gravidarum | D006939 | 2 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Hypoproteinemia | D007019 | 1 associated lipids |
| Immunoproliferative Small Intestinal Disease | D007161 | 2 associated lipids |
| Infant, Premature, Diseases | D007235 | 7 associated lipids |
| Influenza, Human | D007251 | 11 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Iris Diseases | D007499 | 2 associated lipids |
| Iritis | D007500 | 2 associated lipids |
| Ischemia | D007511 | 18 associated lipids |
| Keratoconjunctivitis | D007637 | 3 associated lipids |
| Klebsiella Infections | D007710 | 7 associated lipids |
| Obstetric Labor, Premature | D007752 | 9 associated lipids |
| Legionnaires' Disease | D007877 | 4 associated lipids |
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Leprosy | D007918 | 8 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Adamek RJ et al. | Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. | 1995 | Am. J. Gastroenterol. | pmid:7801936 |
| Jaup BH and Norrby A | Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7771426 |
| Isomoto H et al. | Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. | 2005 | Am. J. Gastroenterol. | pmid:16086706 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Laine L et al. | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. | 2003 | Am. J. Gastroenterol. | pmid:12650788 |
| Take S et al. | Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. | 2003 | Am. J. Gastroenterol. | pmid:14638340 |
| Mohar A et al. | Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. | 2002 | Am. J. Gastroenterol. | pmid:12385434 |
| De Francesco V et al. | Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? | 2002 | Am. J. Gastroenterol. | pmid:12385470 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Peterson WL et al. | Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. | 1993 | Am. J. Gastroenterol. | pmid:8237933 |
| Froehlich F et al. | Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. | 2001 | Am. J. Gastroenterol. | pmid:11513170 |
| Sánchez-Delgado J et al. | Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. | 2008 | Am. J. Gastroenterol. | pmid:18564109 |
| Hansen JM et al. | Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. | 2008 | Am. J. Gastroenterol. | pmid:18445098 |
| Vakil N | H. pylori treatment: new wine in old bottles? | 2009 | Am. J. Gastroenterol. | pmid:19098845 |
| Rokkas T et al. | Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. | 2009 | Am. J. Gastroenterol. | pmid:19098844 |
| Sapone A et al. | The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. | 2003 | Am. J. Gastroenterol. | pmid:12809821 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Levy M et al. | Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. | 2002 | Am. J. Gastroenterol. | pmid:11866264 |
| Christopher K et al. | Clarithromycin use preceding fulminant hepatic failure. | 2002 | Am. J. Gastroenterol. | pmid:11866297 |
| Suzuki S et al. | The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. | 2016 | Am. J. Gastroenterol. | pmid:27185079 |
| Vakil N et al. | Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. | 1998 | Am. J. Gastroenterol. | pmid:9732920 |
| Chu KM et al. | A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. | 1998 | Am. J. Gastroenterol. | pmid:9732921 |
| Lamouliatte H et al. | Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. | 1998 | Am. J. Gastroenterol. | pmid:9732938 |
| Lerang F et al. | Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? | 1997 | Am. J. Gastroenterol. | pmid:9040200 |
| Chey WD et al. | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. | 1997 | Am. J. Gastroenterol. | pmid:9317068 |
| Gatta L et al. | Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. | 2009 | Am. J. Gastroenterol. | pmid:19844205 |
| Ozmen MM and Johnson CD | Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? | 1995 | Am. J. Gastroenterol. | pmid:7661197 |
| Kim CG et al. | Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. | 2008 | Am. J. Gastroenterol. | pmid:17714557 |
| Savarino V et al. | New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. | 1995 | Am. J. Gastroenterol. | pmid:7717343 |
| Zullo A et al. | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. | 1997 | Am. J. Gastroenterol. | pmid:9362185 |
| Moayyedi P and Malfertheiner P | Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? | 2009 | Am. J. Gastroenterol. | pmid:19956122 |
| Zullo A et al. | A quintuple therapy for H. pylori eradication. | 2007 | Am. J. Gastroenterol. | pmid:17958765 |
| Schwartz H et al. | Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. | 1998 | Am. J. Gastroenterol. | pmid:9576452 |
| Calvet X et al. | Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. | 2005 | Am. J. Gastroenterol. | pmid:16086704 |
| Park CS et al. | Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. | 2014 | Am. J. Gastroenterol. | pmid:25091062 |
| Vakil N | Helicobacter pylori treatment: a practical approach. | 2006 | Am. J. Gastroenterol. | pmid:16542285 |
| Santander C et al. | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. | 1996 | Am. J. Gastroenterol. | pmid:8759659 |
| Tursi A et al. | Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. | 1996 | Am. J. Gastroenterol. | pmid:8759696 |
| Bytzer P | Management of the dyspeptic patient: anything goes? | 2006 | Am. J. Gastroenterol. | pmid:16771938 |
| Manes G et al. | Eradication of Helicobacter pylori and dosages of esomeprazole. | 2006 | Am. J. Gastroenterol. | pmid:16771971 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| Fuccio L et al. | Can sequential therapy for Helicobacter pylori eradication overcome clarithromycin resistance?: Data still do not support conclusions. | 2010 | Am. J. Gastroenterol. | pmid:20606668 |
| Laine L et al. | Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. | 2000 | Am. J. Gastroenterol. | pmid:11151867 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Nakao K et al. | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. | 1997 | Am. J. Gastroenterol. | pmid:9177520 |
| Maconi G et al. | Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? | 2001 | Am. J. Gastroenterol. | pmid:11232676 |
| Nam SY et al. | Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. | 2010 | Am. J. Gastroenterol. | pmid:20571493 |
| Veldhuyzen van Zanten S et al. | Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. | 2003 | Am. J. Gastroenterol. | pmid:14499772 |
| Luther J et al. | Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. | 2010 | Am. J. Gastroenterol. | pmid:19755966 |